Abdelrahman Mahmoud

Abdelrahman Mahmoud

Auto-generated profile, based on publicly available information

Abdelrahman Mahmoud

German Cancer Research Center, Division of Applied Bioinformatics, Heidelberg, Germany 3

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2016 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
AAAbdelRahman Mahmoud Aly
AbdelRahman Mahmoud Aly
AAAbdelReheem Adel
AbdelReheem Adel
Ahmed Osama El-GendyAhmed Osama El-Gendy
Ahmed Osama El-Gendy
TETamer M. Essam
Tamer M. Essam
Ramy AzizRamy Aziz
Ramy Aziz
Hepatitis C virus (HCV) causes debilitating liver diseases, which may progress to cirrhosis and cancer, and claims 500,000 annual lives worldwide. While HCV epidemiology, pathophysiology, and therapy are being deeply studied, rare attention is given to reciprocal interactions between HCV infection , HCV-induced chronic liver diseases, and the human gut microbiome. As Egypt has the world’s highest prevalence of HCV infections, we launched this study to monitor differences in the gut microbial community composition of Egyptian HCV patients that may affect, or result from, the patients’ liver state. To this end, we analyzed stool samples from six stage 4-HCV patients and eight healthy individuals by high-throughput 16S rRNA gene sequencing using Illumina MiSeq. Overall, the alpha-diversity of the healthy persons’ gut microbiomes was higher than those of the HCV patients. Whereas members of phylum Bacteroidetes were more abundant in HCV patients, healthy individuals had higher abundance of Firmicutes, Proteobacteria, and Actinobacteria. Genus-level analysis showed differential abundance of Prevotella and Faecalibacterium (higher in HCV patients) vs. Ruminococcus and Clostridium (healthy group), indicating that the higher abundance of Bacteroidetes in HCV patients is most likely due to Prevotella overabundance. The probiotic genus, Bifidobacterium, was only observed in the microbiotas of healthy individuals. To the best of our knowledge, this study provides a first overview of major phyla and genera differentiating stage 4-HCV patients from healthy individuals and suggests possible microbiome remodeling in chronic hepatitis C, possibly shaped by bacterial translocation as well as the liver’s impaired role in digestion and protein synthesis. Future studies will investigate the microbiome composition and functional capabilities in more patients while tracing some potential biomarker taxa (e.g., Prevotella, Faecalibacterium vs. Bifidobacterium).

4 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JVJulia Varga
Julia Varga
ANAdele Nicolas
Adele Nicolas
VPValentina Petrocelli
Valentina Petrocelli
MPMarina Pesic
Marina Pesic
AMAbdelrahman Mahmoud
Abdelrahman Mahmoud
FGFlorian Greten
Florian Greten
Recently, a transcriptome-based consensus molecular subtype (CMS) classification of colorectal cancer (CRC) has been established, which may ultimately help to individualize CRC therapy. However, the lack of animal models that faithfully recapitulate the different molecular subtypes impedes adequate preclinical testing of stratified therapeutic concepts. Here, we demonstrate that constitutive AKT activation in intestinal epithelial cells markedly enhances tumor invasion and metastasis in Trp53ΔIEC mice (Trp53ΔIECAktE17K) upon challenge with the carcinogen azoxymethane. Gene-expression profiling indicates that Trp53ΔIECAktE17K tumors resemble the human mesenchymal colorectal cancer subtype (CMS4), which is characterized by the poorest survival rate among the four CMSs. Trp53ΔIECAktE17K tumor cells are characterized by Notch3 up-regulation, and treatment of Trp53ΔIECAktE17K mice with a NOTCH3-inhibiting antibody reduces invasion and metastasis. In CRC patients, NOTCH3 expression correlates positively with tumor grading and the presence of lymph node as well as distant metastases and is specifically up-regulated in CMS4 tumors. Therefore, we suggest NOTCH3 as a putative target for advanced CMS4 CRC patients.

6 December 2017 in Leukemia
Verified
Journal Article
Open access
PDF file
ITI Tirado-Gonzalez
I Tirado-Gonzalez
ECE Czlonka
E Czlonka
ANA Nevmerzhitskaya
A Nevmerzhitskaya
DSD Soetopo
D Soetopo
EBE Bergonzani
E Bergonzani
HMH Medyouf
H Medyouf
Leukemia accepted article preview online, 06 December 2017. doi:10.1038/leu.2017.346.